jardiamet
boehringer ingelheim (nz) limited - empagliflozin 5mg; ; metformin hydrochloride 1000mg; - film coated tablet - 5mg/1000mg - active: empagliflozin 5mg metformin hydrochloride 1000mg excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry yellow 02b220012 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.
jardiamet
boehringer ingelheim (nz) limited - empagliflozin 5mg; ; metformin hydrochloride 500mg; - film coated tablet - 5mg/500mg - active: empagliflozin 5mg metformin hydrochloride 500mg excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry yellow 02b220011 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.
jardiamet
boehringer ingelheim (nz) limited - empagliflozin 5mg; ; metformin hydrochloride 850mg; - film coated tablet - 5mg/850mg - active: empagliflozin 5mg metformin hydrochloride 850mg excipient: colloidal silicon dioxide copovidone magnesium stearate maize starch opadry yellow 02b220010 - glycaemic control jardiamet is indicated as an adjunct to diet and exercise to improve glycaemic control in adult patients with type 2 diabetes mellitus: · when treatment with both empagliflozin and metformin is appropriate ·inadequately controlled with metformin or empagliflozin alone ·inadequately controlled with empagliflozin or metformin in combination with other glucose-lowering products including insulin · already treated with empagliflozin and metformin co-administered as separate tablets.
diarrcell anti-diarrhoea powder
nutrien ag solutions limited - catechu = catechu black = cachou - oral powder, pre-mix - catechu = catechu black = cachou extract-plant active 30.0 mg/g - alimentary system - cattle | goat | horse | pigs | sheep | beef | billy | boar | bos indicus | bos taurus | bovine | buck | buffalo | bull | bullock - diarrhoea | absorptive | acute diarrhoea | acute intestinal catarrh | avian blackhead | bacterial enteritis | blackhead | chronic diarrhoea | coccidiosis | dietary factors | dietary upset | enteritis | feed conversion | flatulance | fluid loss | gastro-intestinal | gram negative bacteria | growth rate | k88+ serotypes of e.coli | nesting diarrhoea | non-specific irritants | poisoning | postweaning scours | prophylactic | scours | streptomycin sensitive bacteri | sulphadiazine sensitive bacter | sulphonamide sensitive bacteri | trichomoniasis | trimethoprim sensitive bacteri | white scours
m-ediat capsule (immediate release)
ethypharm inc - morphine sulfate - capsule (immediate release) - 5mg - morphine sulfate 5mg - opiate agonists
m-ediat capsule (immediate release)
ethypharm inc - morphine sulfate - capsule (immediate release) - 10mg - morphine sulfate 10mg - opiate agonists
m-ediat capsule (immediate release)
ethypharm inc - morphine sulfate - capsule (immediate release) - 20mg - morphine sulfate 20mg - opiate agonists
m-ediat capsule (immediate release)
ethypharm inc - morphine sulfate - capsule (immediate release) - 30mg - morphine sulfate 30mg - opiate agonists
kadian morphine sulfate capsule extended release
actavis kadian llc - morphine sulfate (unii: x3p646a2j0) (morphine - unii:76i7g6d29c) - morphine sulfate 10 mg
diastat- diazepam gel
bausch health us, llc - diazepam (unii: q3jtx2q7tu) (diazepam - unii:q3jtx2q7tu) - diazepam 2.5 mg in 0.5 ml - diazepam rectal gel is intended for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 2 years of age and older. diazepam rectal gel is contraindicated in patients with a known hypersensitivity to diazepam. diazepam rectal gel may be used in patients with open angle glaucoma who are receiving appropriate therapy but is contraindicated in acute narrow angle glaucoma. controlled substance: diastat contains diazepam, a schedule iv controlled substance. abuse: diastat is a benzodiazepine and a cns depressant with a potential for abuse and addiction. abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects. misuse is the intentional use, for therapeutic purposes, of a drug by an individual in a way other than prescribed by a health care provider or for whom it was not prescribed.